Alla Dolnikov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alla Dolnikov has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Sylvie Shen
Sydney Children's Hospital, Randwick, New South Wales, Australia
6 shared publications Ning Xu
Cord & Marrow Transplant Facility, Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia; Children's Cancer Institute Australia, Sydney, Australia
4 shared publications- Robert E. Nordon
Graduate School of Biomedical Engineering, University of New South Wales, Sydney, NSW 2052, Australia
3 shared publications Susan Yang
Children's Cancer Institute, Sydney, New South Wales, Australia
3 shared publicationsTiffany Holmes
Sydney Cord and Marrow Transplant Facility, Centre for Children's Cancer and Blood Disorders, Sydney Children's Hospital, Randwick, Sydney, Australia
3 shared publications- Tracey A. O'Brien
Cord & Marrow Transplant Facility, Kids Cancer Centre, Sydney Children's Hospital, Sydney, Australia; Faculty of Medicine, University of New South Wales, Sydney, Australia; Children's Cancer Institute Australia, Sydney, Australia
3 shared publications
Latest Publications
- 15 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (12) , 1001-1014.e5
Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia
- 15 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (12) , 1001-1014.e5
Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia
- 1 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (9) , S60
Declined presentation T-cell precursors to generate chimeric antigen receptor (CAR)-modified t cells
- 1 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (9) , S60
Declined presentation T-cell precursors to generate chimeric antigen receptor (CAR)-modified t cells
- 1 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (9) , S59
Declined presentation one dose of 5-AZA-2'-Deoxycytidine enhances therapeutic efficacy of cart-cell therapy in a murine model by improving T-cell persistence
- 1 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (9) , S59
Declined presentation one dose of 5-AZA-2'-Deoxycytidine enhances therapeutic efficacy of cart-cell therapy in a murine model by improving T-cell persistence
- 1 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (9) , S59
Declined presentation stem cell approach to generate chimeric antigen receptor modified immune effector cells
- 1 September 2015
- Published by Elsevier in Experimental Hematology
- Vol. 43 (9) , S59
Declined presentation stem cell approach to generate chimeric antigen receptor modified immune effector cells
- 12 February 2014
- Published by Wiley in Cell Proliferation
- Vol. 47 (2) , 113-123
GSK‐3β inhibition promotes early engraftment of ex vivo‐expanded haematopoietic stem cells
Objectives: Umbilical cord blood (UCB) is a source of stem cells used for allogeneic transplantation, in addition to bone marrow and peripheral blood. Limited numbers of stem cells in a single UCB unit is associated with slow haematopoietic recovery and high risk of graft failure, particularly in adult patients. UCB stem cells can be expanded ex vivo; however, rapid differentiation reduces their regenerative potential. We have recently shown that Wnt/β‐catenin signalling is down‐regulated in ex vivo‐expanded stem cells; therefore, we propose that re‐activation of Wnt signalling using GSK‐3β inhibition may act to improve regenerative potential of these ex vivo‐expanded stem cells.Materials and methods: Immunocompromised mice were employed in transplantation studies to determine stem‐cell engraftment. Flow cytometry was used to phenotype the engrafted human cells. Retroviral gene transfer was used to examine the role of Myc gene up‐regulated by GSK‐3β inhibition, in ex vivo‐expanded stem cells.Results: Treatment with GSK‐3β inhibitor, 6‐bromoindirubin 3′‐oxime (BIO) improved early human cell engraftment in the mice and elevated the numbers of myeloid progenitor cells in cytokine‐stimulated culture. BIO up‐regulated β‐catenin and c‐myc in ex vivo‐expanded stem cells. Ectopic expression of Myc acted to increase clonogenic potential and to delay differentiation of haematopoietic progenitor cells, suggesting the potential mechanism to improve regenerative potential of ex vivo‐expanded grafts.Conclusions: Pharmacological inhibition of GSK‐3β provided a novel approach to improve early engraftment of ex vivo‐expanded haematopoietic progenitor cells.
- 12 February 2014
- Published by Wiley in Cell Proliferation
- Vol. 47 (2) , 113-123
GSK‐3β inhibition promotes early engraftment of ex vivo‐expanded haematopoietic stem cells
Objectives: Umbilical cord blood (UCB) is a source of stem cells used for allogeneic transplantation, in addition to bone marrow and peripheral blood. Limited numbers of stem cells in a single UCB unit is associated with slow haematopoietic recovery and high risk of graft failure, particularly in adult patients. UCB stem cells can be expanded ex vivo; however, rapid differentiation reduces their regenerative potential. We have recently shown that Wnt/β‐catenin signalling is down‐regulated in ex vivo‐expanded stem cells; therefore, we propose that re‐activation of Wnt signalling using GSK‐3β inhibition may act to improve regenerative potential of these ex vivo‐expanded stem cells.Materials and methods: Immunocompromised mice were employed in transplantation studies to determine stem‐cell engraftment. Flow cytometry was used to phenotype the engrafted human cells. Retroviral gene transfer was used to examine the role of Myc gene up‐regulated by GSK‐3β inhibition, in ex vivo‐expanded stem cells.Results: Treatment with GSK‐3β inhibitor, 6‐bromoindirubin 3′‐oxime (BIO) improved early human cell engraftment in the mice and elevated the numbers of myeloid progenitor cells in cytokine‐stimulated culture. BIO up‐regulated β‐catenin and c‐myc in ex vivo‐expanded stem cells. Ectopic expression of Myc acted to increase clonogenic potential and to delay differentiation of haematopoietic progenitor cells, suggesting the potential mechanism to improve regenerative potential of ex vivo‐expanded grafts.Conclusions: Pharmacological inhibition of GSK‐3β provided a novel approach to improve early engraftment of ex vivo‐expanded haematopoietic progenitor cells.
- 20 March 2012
- Published by Wiley in Cell Proliferation
- Vol. 45 (3) , 266-278
Ex vivo expansion of cord blood progenitors impairs their short‐term and long‐term repopulating activity associated with transcriptional dysregulation of signalling networks
Objectives: Cord blood (CB) has been established to be an alternative source of haematopoietic stem/progenitor cells (HPC) for transplantation. The number of HPC per CB unit is limited, which results in engraftment delay. Ex vivo expansion of HPC improvement must overcome this.Materials and methods: Flow cytometry was used to extensively phenotype HPC pre‐ and post‐expansion and CFDA‐SE staining was used to track cell divisions. The NSG mouse model was employed in transplantation studies to determine long and short term repopulation in human cells. Gene array analysis was used to evaluate signalling pathways regulated following ex vivo expansion of HPC.Results: expansion of CD34+ HPC impaired their regenerative function. In this xenograft transplantation model we showed that repopulating activity of CB cells declined following expansion. Expanded HPC had delayed engraftment at early and late stages post‐transplant. High resolution division tracking revealed that the cultured HPC had reduced expansion and self‐renewal probability and increased differentiation rate compared to non‐expanded cells. Gene expression analysis exposed significant modulation of a complex network of genes and pathways that normally maintain HPC proliferation and limit their differentiation.Conclusions: The decline in short‐term engraftment is consistent with the loss of rapid SCID repopulating ability r(SRA) by expanded CD34+CD38+ cells recently reported (1). Our data raise concerns for future clinical applications of expanded HPC alone in transplantation.
- 20 March 2012
- Published by Wiley in Cell Proliferation
- Vol. 45 (3) , 266-278
Ex vivo expansion of cord blood progenitors impairs their short‐term and long‐term repopulating activity associated with transcriptional dysregulation of signalling networks
Objectives: Cord blood (CB) has been established to be an alternative source of haematopoietic stem/progenitor cells (HPC) for transplantation. The number of HPC per CB unit is limited, which results in engraftment delay. Ex vivo expansion of HPC improvement must overcome this.Materials and methods: Flow cytometry was used to extensively phenotype HPC pre‐ and post‐expansion and CFDA‐SE staining was used to track cell divisions. The NSG mouse model was employed in transplantation studies to determine long and short term repopulation in human cells. Gene array analysis was used to evaluate signalling pathways regulated following ex vivo expansion of HPC.Results: expansion of CD34+ HPC impaired their regenerative function. In this xenograft transplantation model we showed that repopulating activity of CB cells declined following expansion. Expanded HPC had delayed engraftment at early and late stages post‐transplant. High resolution division tracking revealed that the cultured HPC had reduced expansion and self‐renewal probability and increased differentiation rate compared to non‐expanded cells. Gene expression analysis exposed significant modulation of a complex network of genes and pathways that normally maintain HPC proliferation and limit their differentiation.Conclusions: The decline in short‐term engraftment is consistent with the loss of rapid SCID repopulating ability r(SRA) by expanded CD34+CD38+ cells recently reported (1). Our data raise concerns for future clinical applications of expanded HPC alone in transplantation.
- 24 June 2011
- Published by Springer Nature
- Vol. 761, 249-260
Ex Vivo Expansion of Haematopoietic Stem Cells to Improve Engraftment in Stem Cell Transplantation
The efficient use of haematopoietic stem cells (HSC) for transplantation is often limited by the relatively low numbers of HSC collected. The ex vivo expansion of HSC for clinical use is a potentially valuable and safe approach to increase HSC numbers thereby increasing engraftment and reducing the risk of morbidity from infection. Here we describe a protocol for the robust ex vivo expansion of human CD34(+) HSC isolated from umbilical cord blood. The protocol described can efficiently generate large numbers of HSC. We also describe a flow cytometry-based method using high resolution division tracking to characterise the kinetics of HSC growth and differentiation. Utilising the guidelines discussed, it is possible for investigators to use this protocol as presented or to modify it for their specific needs.
- 24 June 2011
- Published by Springer Nature
- Vol. 761, 249-260
Ex Vivo Expansion of Haematopoietic Stem Cells to Improve Engraftment in Stem Cell Transplantation
The efficient use of haematopoietic stem cells (HSC) for transplantation is often limited by the relatively low numbers of HSC collected. The ex vivo expansion of HSC for clinical use is a potentially valuable and safe approach to increase HSC numbers thereby increasing engraftment and reducing the risk of morbidity from infection. Here we describe a protocol for the robust ex vivo expansion of human CD34(+) HSC isolated from umbilical cord blood. The protocol described can efficiently generate large numbers of HSC. We also describe a flow cytometry-based method using high resolution division tracking to characterise the kinetics of HSC growth and differentiation. Utilising the guidelines discussed, it is possible for investigators to use this protocol as presented or to modify it for their specific needs.
- Open Access
- 19 October 2010
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 29 (1) , 108-118
GSK-3β Inhibition Promotes Engraftment of Ex Vivo-Expanded Hematopoietic Stem Cells and Modulates Gene Expression
Glycogen synthase kinase-3β (GSK-3β) has been identified as an important regulator of stem cell function acting through activation of the wingless (Wnt) pathway. Here, we report that treatment with an inhibitor of GSK-3β, 6-bromoindirubin 3′-oxime (BIO) delayed cell cycle progression by increasing cell cycle time. BIO treatment resulted in the accumulation of late dividing cells enriched with primitive progenitor cells retaining the ability for sustained proliferation. In vivo analysis using a Non-obese diabetic/severe combined immunodeficient (NOD/SCID) transplantation model has demonstrated that pretreatment with BIO promotes engraftment of ex vivo-expanded hematopoietic stem cells. BIO enhanced the engraftment of myeloid, lymphoid and primitive stem cell compartments. Limiting dilution analysis of SCID repopulating cells (SRC) revealed that BIO treatment increased human chimerism without increasing SRC frequency. Clonogenic analysis of human cells derived from the bone marrow of transplant recipient mice demonstrated that a higher level of human chimerism and cellularity was related to increased regeneration per SRC unit. Gene expression analysis showed that treatment with BIO did not modulate the expression of canonical Wnt target genes upregulated during cytokine-induced cell proliferation. BIO increased the expression of several genes regulating Notch and Tie2 signaling downregulated during ex vivo expansion, suggesting a role in improving stem cell engraftment. In addition, treatment with BIO upregulated CDK inhibitor p57 and downregulated cyclin D1, providing a possible mechanism for the delay seen in cell cycle progression. We conclude that transient, pharmacologic inhibition of GSK-3β provides a novel approach to improve engraftment of expanded HSC after stem cell transplantation.
- 19 October 2010
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 29 (1) , 108-118
Open AccessGSK-3β Inhibition Promotes Engraftment of Ex Vivo-Expanded Hematopoietic Stem Cells and Modulates Gene Expression
Glycogen synthase kinase-3β (GSK-3β) has been identified as an important regulator of stem cell function acting through activation of the wingless (Wnt) pathway. Here, we report that treatment with an inhibitor of GSK-3β, 6-bromoindirubin 3′-oxime (BIO) delayed cell cycle progression by increasing cell cycle time. BIO treatment resulted in the accumulation of late dividing cells enriched with primitive progenitor cells retaining the ability for sustained proliferation. In vivo analysis using a Non-obese diabetic/severe combined immunodeficient (NOD/SCID) transplantation model has demonstrated that pretreatment with BIO promotes engraftment of ex vivo-expanded hematopoietic stem cells. BIO enhanced the engraftment of myeloid, lymphoid and primitive stem cell compartments. Limiting dilution analysis of SCID repopulating cells (SRC) revealed that BIO treatment increased human chimerism without increasing SRC frequency. Clonogenic analysis of human cells derived from the bone marrow of transplant recipient mice demonstrated that a higher level of human chimerism and cellularity was related to increased regeneration per SRC unit. Gene expression analysis showed that treatment with BIO did not modulate the expression of canonical Wnt target genes upregulated during cytokine-induced cell proliferation. BIO increased the expression of several genes regulating Notch and Tie2 signaling downregulated during ex vivo expansion, suggesting a role in improving stem cell engraftment. In addition, treatment with BIO upregulated CDK inhibitor p57 and downregulated cyclin D1, providing a possible mechanism for the delay seen in cell cycle progression. We conclude that transient, pharmacologic inhibition of GSK-3β provides a novel approach to improve engraftment of expanded HSC after stem cell transplantation.
- 1 July 2008
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 33 (1) , 175-183
siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth
Interferon regulatory factor (IRF) 1 and its functional antagonist IRF2 were originally discovered as transcription factors that regulate the interferon-β gene. Control of cell growth has led to the definition of IRF1 as a tumour suppressor gene and IRF2 as an oncogene. Clinically, approximately 70% of cases of acute myeloid leukaemia demonstrate dysregulated expression of IRF1 and/or IRF2. Our previous studies have shown that human leukaemic TF-1 cells exhibit abnormally high expression of both IRF1 and IRF2, the latter acting to abrogate IRF1 tumour suppression, making these cells ideal for analysis of down-regulation of IRF2 expression. A novel G418 screening protocol was developed and used for identifying effective siRNA that targets IRF2 (siIRF2). Using optimized siIRF2 in leukaemic TF-1 cells, IRF2 was down-regulated by approximately 70% at both mRNA and protein levels. Phenotypically, this resulted in growth inhibition associated with G2/M arrest as well as induction of polyploidy, differentiation and apoptosis. In contrast to these results, siIRF2 targeting did not affect normal haematopoietic stem/progenitor cell growth. These results indicate the potential utility of IRF2 inhibition as a therapeutic approach to cancer.
- 1 July 2008
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 33 (1) , 175-183
siRNA targeting the IRF2 transcription factor inhibits leukaemic cell growth
Interferon regulatory factor (IRF) 1 and its functional antagonist IRF2 were originally discovered as transcription factors that regulate the interferon-β gene. Control of cell growth has led to the definition of IRF1 as a tumour suppressor gene and IRF2 as an oncogene. Clinically, approximately 70% of cases of acute myeloid leukaemia demonstrate dysregulated expression of IRF1 and/or IRF2. Our previous studies have shown that human leukaemic TF-1 cells exhibit abnormally high expression of both IRF1 and IRF2, the latter acting to abrogate IRF1 tumour suppression, making these cells ideal for analysis of down-regulation of IRF2 expression. A novel G418 screening protocol was developed and used for identifying effective siRNA that targets IRF2 (siIRF2). Using optimized siIRF2 in leukaemic TF-1 cells, IRF2 was down-regulated by approximately 70% at both mRNA and protein levels. Phenotypically, this resulted in growth inhibition associated with G2/M arrest as well as induction of polyploidy, differentiation and apoptosis. In contrast to these results, siIRF2 targeting did not affect normal haematopoietic stem/progenitor cell growth. These results indicate the potential utility of IRF2 inhibition as a therapeutic approach to cancer.
- Open Access
- 6 March 2008
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 26 (5) , 1288-1297
Glycogen Synthase Kinase-3β Inhibition Preserves Hematopoietic Stem Cell Activity and Inhibits Leukemic Cell Growth
Ex vivo expansion of cord blood cells generally results in reduced stem cell activity in vivo. Glycogen synthase kinase-3β (GSK-3β) regulates the degradation of β-catenin, a critical regulator of hematopoietic stem cells (HSCs). Here we show that GSK-3β inhibition activates β-catenin in cord blood CD34+ cells and upregulates β-catenin transcriptional targets c-myc and HoxB4, both known to regulate HSC self-renewal. GSK-3β inhibition resulted in delayed ex vivo expansion of CD34+ cells, yet enhanced the preservation of stem cell activity as tested in long-term culture with bone marrow stroma. Delayed cell cycling, reduced apoptosis, and increased adherence of hematopoietic progenitor cells to bone marrow stroma were observed in these long-term cultures treated with GSK-3β inhibitor. This improved adherence to stroma was mediated via upregulation of CXCR4. In addition, GSK-3β inhibition preserved severe combined immunodeficiency (SCID) repopulating cells as tested in the nonobese diabetic/SCID mouse model. Our data suggest the involvement of GSK-3β inhibition in the preservation of HSC and their interaction with the bone marrow environment. Methods for the inhibition of GSK-3β may be developed for clinical ex vivo expansion of HSC for transplantation. In addition, GSK-3β inhibition suppressed leukemic cell growth via the induction of apoptosis mediated by the downregulation of survivin. Modulators of GSK-3β may increase the range of novel drugs that specifically kill leukemic cells while sparing normal stem cells. Disclosure of potential conflicts of interest is found at the end of this article.
- 6 March 2008
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 26 (5) , 1288-1297
Open AccessGlycogen Synthase Kinase-3β Inhibition Preserves Hematopoietic Stem Cell Activity and Inhibits Leukemic Cell Growth
Ex vivo expansion of cord blood cells generally results in reduced stem cell activity in vivo. Glycogen synthase kinase-3β (GSK-3β) regulates the degradation of β-catenin, a critical regulator of hematopoietic stem cells (HSCs). Here we show that GSK-3β inhibition activates β-catenin in cord blood CD34+ cells and upregulates β-catenin transcriptional targets c-myc and HoxB4, both known to regulate HSC self-renewal. GSK-3β inhibition resulted in delayed ex vivo expansion of CD34+ cells, yet enhanced the preservation of stem cell activity as tested in long-term culture with bone marrow stroma. Delayed cell cycling, reduced apoptosis, and increased adherence of hematopoietic progenitor cells to bone marrow stroma were observed in these long-term cultures treated with GSK-3β inhibitor. This improved adherence to stroma was mediated via upregulation of CXCR4. In addition, GSK-3β inhibition preserved severe combined immunodeficiency (SCID) repopulating cells as tested in the nonobese diabetic/SCID mouse model. Our data suggest the involvement of GSK-3β inhibition in the preservation of HSC and their interaction with the bone marrow environment. Methods for the inhibition of GSK-3β may be developed for clinical ex vivo expansion of HSC for transplantation. In addition, GSK-3β inhibition suppressed leukemic cell growth via the induction of apoptosis mediated by the downregulation of survivin. Modulators of GSK-3β may increase the range of novel drugs that specifically kill leukemic cells while sparing normal stem cells. Disclosure of potential conflicts of interest is found at the end of this article.